What is the recommended diagnostic test for pheochromocytoma?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 28, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Diagnostic Testing for Pheochromocytoma

The measurement of plasma free metanephrines is the recommended first-line diagnostic test for pheochromocytoma, with the highest sensitivity (96-100%) and specificity (89-98%) among all biochemical tests. 1, 2

Primary Diagnostic Tests

  • Plasma free metanephrines is the preferred initial test due to its superior diagnostic performance, with nearly 100% sensitivity for detecting pheochromocytoma 1, 3
  • Urinary fractionated metanephrines is an acceptable alternative with high sensitivity (86-97%) and specificity (86-95%) 1, 2
  • For optimal results, plasma free metanephrines should be collected from an indwelling venous catheter after the patient has been lying supine for 30 minutes to limit false positive results 2

Interpretation of Results

  • Results ≥4 times the upper limit of normal are highly consistent with pheochromocytoma and warrant immediate imaging 1, 2
  • Results 2-4 times the upper limit of normal suggest possible pheochromocytoma; repeat testing in 2 months and consider genetic testing 1, 2
  • Marginally elevated levels (1-2 times upper limit) may represent false positives; consider repeat testing in 6 months and clonidine suppression test 1, 2

Follow-up Testing for Equivocal Results

  • If plasma testing is equivocal (less than fourfold elevation), perform a 24-hour urine collection for catecholamines and metanephrines 1, 2
  • Clonidine suppression testing is recommended in cases of equivocal results with strong clinical suspicion, with 100% specificity and 96% sensitivity 4, 1
  • The clonidine suppression test is regarded as negative when there is a marked reduction of plasma catecholamines 4

Imaging After Biochemical Confirmation

  • MRI is preferred for suspected pheochromocytoma due to risk of hypertensive crisis with IV contrast for CT 1, 2
  • For patients with established pheochromocytoma, FDG-PET appears superior to MIBG for detecting malignant tumors, particularly in patients with SDHB mutation 2
  • If initial imaging is negative but biochemical evidence is positive, extend imaging to include chest and neck, and consider functional imaging 4

Special Considerations

  • Avoid fine needle biopsy of suspected pheochromocytoma as it is contraindicated due to risk of hypertensive crisis 4, 2
  • Approximately 35% of pheochromocytomas/paragangliomas are hereditary, so genetic testing should be considered, especially in younger patients 1, 5
  • Patients with SDHB mutations require more intensive surveillance due to higher risk of malignancy 1, 2
  • For pediatric patients with suspected hereditary syndromes, begin surveillance at age 6-8 years for hereditary paraganglioma/pheochromocytoma syndromes, or age 2 years for von Hippel-Lindau syndrome 1, 2

Common Pitfalls to Avoid

  • False positive elevations are usually <4 times the upper limit of normal and can occur with obesity, obstructive sleep apnea, or use of tricyclic antidepressants 1
  • Failing to ensure proper patient preparation before testing (medications, posture, fasting status) can lead to false results 2
  • Relying solely on imaging without biochemical confirmation is not recommended 2
  • Not considering extra-adrenal locations when adrenal imaging is negative can lead to missed diagnoses 2

Clinical Scenarios Warranting Testing

  • Early-onset hypertension (<30 years) 1
  • Resistant hypertension 1
  • Paroxysmal hypertension with classic symptoms (headache, sweating, palpitations) 1
  • Significant blood pressure variability 1
  • Family history of pheochromocytoma 1

References

Guideline

Diagnosis and Management of Pheochromocytoma in Hypertensive Patients

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Diagnostic Evaluation of Suspected Pheochromocytoma

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Diagnóstico y Manejo del Feocromocitoma

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.